Recombinant immunotoxin 4D5scFv-PE40 for targeted therapy of HER2-positive tumors

E. A. Sokolova, O. A. Stremovskiy, T. A. Zdobnova, I. V. Balalaeva, S. M. Deyev

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Recombinant immunotoxins are extremely promising agents for the targeted therapy of tumors with a certain molecular profile. In this work, we studied the properties of a new recombinant HER2-specific immunotoxin composed of the scFv antibody and a fragment of Pseudomonas exotoxin A (4D5scFv-PE40). High affinity of the immunotoxin for the HER2 tumor marker, its selective cytotoxicity against HER2-overexpressing cells, and its storage stability were demonstrated. The 50% inhibitory concentration (IC50) of the 4D5scFv-PE40 immunotoxin for HER2-overexpressing cancer cells was 2.5-3 orders of magnitude lower compared to that for CHO cells not expressing this tumor marker and was 2.5-3 orders of magnitude lower than IC50 of free PE40 for HER2-overexpressing cancer cells. These findings provide a basis for expecting in the long run high therapeutic index values of the 4D5scFv-PE40 immunotoxin for its use in vivo.

Original languageEnglish
Pages (from-to)93-96
Number of pages4
JournalActa Naturae
Volume7
Issue number4
Publication statusPublished - 2015
Externally publishedYes

Keywords

  • 4D5scFv
  • HER2 tumor marker
  • Pseudomonas exotoxin A
  • Recombinant immunotoxin
  • Targeted therapy

ASJC Scopus subject areas

  • Biochemistry
  • Biotechnology
  • Molecular Biology
  • Molecular Medicine

Fingerprint Dive into the research topics of 'Recombinant immunotoxin 4D5scFv-PE40 for targeted therapy of HER2-positive tumors'. Together they form a unique fingerprint.

  • Cite this

    Sokolova, E. A., Stremovskiy, O. A., Zdobnova, T. A., Balalaeva, I. V., & Deyev, S. M. (2015). Recombinant immunotoxin 4D5scFv-PE40 for targeted therapy of HER2-positive tumors. Acta Naturae, 7(4), 93-96.